{"id":27474,"date":"2021-02-01T12:23:35","date_gmt":"2021-02-01T11:23:35","guid":{"rendered":"https:\/\/kymos.com\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/"},"modified":"2025-12-03T19:00:39","modified_gmt":"2025-12-03T18:00:39","slug":"la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19","status":"publish","type":"post","link":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/","title":{"rendered":"La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID-19"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1170px + 20px );margin-left: calc(-20px \/ 2 );margin-right: calc(-20px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:10px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:10px;--awb-width-medium:100%;--awb-spacing-right-medium:10px;--awb-spacing-left-medium:10px;--awb-width-small:100%;--awb-spacing-right-small:10px;--awb-spacing-left-small:10px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p><span style=\"font-size: 14pt;\">Le nouveau vaccin contre la COVID-19 d\u00e9velopp\u00e9 par Pfizer\/BioNTech a \u00e9t\u00e9 approuv\u00e9 par l&rsquo;EMA en d\u00e9cembre dernier, et celui de Moderna suit d\u00e9sormais la m\u00eame voie. Tous deux reposent sur la technologie de l&rsquo;ARNm et repr\u00e9sentent un type de vaccin tr\u00e8s diff\u00e9rent des vaccins traditionnels. Alors que le grand public commence tout juste \u00e0 d\u00e9couvrir la technologie de l&rsquo;ARNm, le Dr Meike Saul, experte en recherche sur l&rsquo;ARN et collaboratrice de longue date de <a href=\"https:\/\/kymos.com\/fr\/prolytique\/\" data-wpel-link=\"internal\">la soci\u00e9t\u00e9 Prolytic GmbH<\/a> , a \u00e9t\u00e9 invit\u00e9e \u00e0 nous \u00e9clairer sur le monde fascinant de l&rsquo;ARN.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Le Dr Saul dirige un groupe de recherche \u00e0 l&rsquo;Universit\u00e9 technique de Darmstadt et se sp\u00e9cialise dans les microARN (miARN), de petites mol\u00e9cules qui jouent un r\u00f4le important dans diff\u00e9rentes maladies, comme le cancer. \u00ab Les ARN, et les miARN en particulier, sont essentiels en m\u00e9decine personnalis\u00e9e \u00bb, explique le Dr Saul. \u00ab En tant que biomarqueurs, les miARN peuvent servir \u00e0 diagnostiquer une maladie, \u00e0 suivre son \u00e9volution ou \u00e0 \u00e9tablir une stratification des patients. Les ARN constituent \u00e9galement des cibles pour le d\u00e9veloppement de th\u00e9rapies et de vaccins \u00e0 base d&rsquo;ARN. Par exemple, jusqu&rsquo;au d\u00e9but des ann\u00e9es 2020, la technologie des vaccins \u00e0 ARN \u00e9tait consid\u00e9r\u00e9e comme tr\u00e8s prometteuse, mais n&rsquo;\u00e9tait pas encore pr\u00eate pour une commercialisation. La pand\u00e9mie de COVID-19 a chang\u00e9 la donne. Le d\u00e9veloppement de vaccins \u00e0 ARN messager (ARNm) contre la COVID-19 par Pfizer\/BioNTech et Moderna a notamment mis cette technologie sur le devant de la sc\u00e8ne \u00bb, conclut-elle.  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Selon le Dr Saul, les vaccins \u00e0 ARNm r\u00e9cemment homologu\u00e9s ont d\u00e9montr\u00e9 les avantages de la technologie de l&rsquo;ARN, \u00e0 commencer par un d\u00e9veloppement beaucoup plus rapide&nbsp;:<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Ce n&rsquo;est pas un hasard si les vaccins \u00e0 ARNm ont \u00e9t\u00e9 les premiers \u00e0 \u00eatre disponibles. Avec les vaccins classiques, on administre des virus att\u00e9nu\u00e9s ou des prot\u00e9ines virales purifi\u00e9es pour entra\u00eener le syst\u00e8me immunitaire \u00e0 reconna\u00eetre le virus. Leur d\u00e9veloppement est co\u00fbteux, long et peut s&rsquo;accompagner d&rsquo;effets secondaires graves. Les vaccins \u00e0 ARNm sont diff\u00e9rents&nbsp;: le sujet re\u00e7oit une injection d&rsquo;ARNm codant pour un fragment de prot\u00e9ine virale, permettant aux cellules de le traduire et de le produire directement dans l&rsquo;organisme, guidant ainsi le syst\u00e8me immunitaire pour neutraliser le virus.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Quelques avantages des vaccins \u00e0 ARNm par rapport aux vaccins conventionnels&nbsp;:<\/span><\/p>\n<ul>\n<li><span style=\"font-size: 14pt;\">Au bout d&rsquo;un certain temps, l&rsquo;organisme d\u00e9grade l&rsquo;ARNm, ce qui r\u00e9duit les effets secondaires par rapport aux vaccins classiques.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">La production de vaccins \u00e0 ARNm est comparativement moins co\u00fbteuse et peut \u00eatre facilement augment\u00e9e \u00e0 grande \u00e9chelle.<\/span><\/li>\n<li><span style=\"font-size: 14pt;\">Les virus ont tendance \u00e0 changer et \u00e0 muter pour survivre, or les vaccins \u00e0 ARNm sont capables de mieux contrer ces mutations que les vaccins conventionnels.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 14pt;\">Face \u00e0 la menace de nouvelles souches de COVID-19, l&rsquo;adaptabilit\u00e9 des vaccins \u00e0 ARNm repr\u00e9sente une v\u00e9ritable r\u00e9volution dans la lutte contre la pand\u00e9mie.<\/span><br \/>\n<span style=\"font-size: 14pt;\">La docteure Meike Saul revient sur l&rsquo;effet positif de ces nouveaux d\u00e9veloppements sur ses travaux sur l&rsquo;ARN \u00e0 l&rsquo;universit\u00e9 technique de Darmstadt et sur sa coop\u00e9ration avec Prolytic, filiale de Kymos&nbsp;:<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u00ab Mes recherches visent \u00e0 identifier de nouvelles fonctionnalit\u00e9s des microARN et leur r\u00f4le dans la communication intercellulaire dans le cancer et les maladies auto-immunes. L\u2019objectif est de transposer ces d\u00e9couvertes en applications cliniques afin d\u2019am\u00e9liorer les strat\u00e9gies de traitement, gr\u00e2ce \u00e0 de nouvelles th\u00e9rapies \u00e0 base d\u2019ARN et de biomarqueurs bas\u00e9s sur les microARN. C\u2019est pourquoi nous avons entam\u00e9 notre collaboration avec Prolytic. \u00bb<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Elle d\u00e9clare : \u00ab Le besoin d&rsquo;analyses d&rsquo;ARN fiables est plus important que jamais, maintenant que les vaccins \u00e0 ARNm sont bien mieux accept\u00e9s par l&rsquo;industrie pharmaceutique, les investisseurs et les gouvernements. C&rsquo;est pourquoi nous nous sommes associ\u00e9s aux experts en bioanalyse BPL de Prolytic pour lancer deux projets de recherche sur l&rsquo;ARN financ\u00e9s par l&rsquo;\u00c9tat f\u00e9d\u00e9ral : le premier, achev\u00e9 en 2019, portait sur le d\u00e9veloppement et la validation d&rsquo;une m\u00e9thode analytique de quantification des microARN plasmatiques selon les BPL. Le second, actuellement en cours, vise \u00e0 d\u00e9velopper un kit de diagnostic du cancer du poumon utilisant le miR-574-5p comme marqueur tumoral et de stratification dans une \u00e9tude de validation men\u00e9e aupr\u00e8s d&rsquo;environ 150 patients atteints de cancer du poumon. Cette collaboration avec Prolytic a permis d&rsquo;obtenir un financement d&rsquo;environ 1,7 million d&rsquo;euros et ambitionne d&rsquo;am\u00e9liorer les traitements anticanc\u00e9reux. \u00c0 l&rsquo;instar des vaccins \u00e0 ARNm, les biomarqueurs microARN peuvent accro\u00eetre l&rsquo;efficacit\u00e9 des th\u00e9rapies anticanc\u00e9reuses de mani\u00e8re in\u00e9dite. \u00bb    <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u00c0 ce stade, le Dr Meike Saul souligne l&rsquo;importance de la collaboration avec Prolytic&nbsp;:<\/span><br \/>\n<span style=\"font-size: 14pt;\">\u00ab&nbsp;De mani\u00e8re g\u00e9n\u00e9rale, l\u2019analyse des ARNm et m\u00eame des miARN n\u2019est pas si difficile&nbsp;; cependant, la mise au point de m\u00e9thodes robustes permettant d\u2019obtenir des r\u00e9sultats pertinents est plus complexe. L\u2019\u00e9quipe de Prolytic a \u00e9t\u00e9 un partenaire de collaboration essentiel. Gr\u00e2ce \u00e0 ses 30&nbsp;ans d\u2019exp\u00e9rience en bioanalyse et \u00e0 son vaste savoir-faire dans diff\u00e9rentes techniques, types d\u2019\u00e9tudes et groupes de substances, nous avons pu d\u00e9velopper rapidement une m\u00e9thode d\u2019analyse reproductible et fiable pour les miARN.&nbsp;\u00bb  <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Prolytic a \u00e9tendu son expertise aux siRNA, ARNm et ADN, en compl\u00e9ment de ses collaborations de recherche avec le Dr Saul. Un nouveau dispositif bas\u00e9 sur des billes magn\u00e9tiques \u00e0 haut et moyen d\u00e9bit permet \u00e0 Prolytic d&rsquo;isoler et de purifier automatiquement les acides nucl\u00e9iques, les prot\u00e9ines et les cellules. Ceci acc\u00e9l\u00e8re consid\u00e9rablement l&rsquo;analyse des oligonucl\u00e9otides. \u00c0 ce jour, Prolytic a accompagn\u00e9 ses clients dans leurs projets de recherche sur les oligonucl\u00e9otides utilis\u00e9s comme biomarqueurs, vaccins ou ARN th\u00e9rapeutiques. D\u00e9sormais membre du groupe Kymos, Prolytic enrichira son offre gr\u00e2ce \u00e0 un savoir-faire accru en mati\u00e8re de tests d&rsquo;activit\u00e9 vaccinale et visera la certification BPF (Bonnes Pratiques de Fabrication) afin de proposer des services CMC (Chimie, Fabrication et Contr\u00f4le) pour les m\u00e9dicaments de th\u00e9rapie innovante. L&rsquo;objectif est d&rsquo;accompagner les clients jusqu&rsquo;\u00e0 la lib\u00e9ration des lots et la production.    <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Les vaccins Pfizer\/BioNTech et Moderna seront sans aucun doute suivis de nombreuses autres applications de la technologie de l&rsquo;ARN. Les \u00e9quipes de Kymos et de leur filiale allemande Prolytic ont l&rsquo;opportunit\u00e9 d&rsquo;accompagner la mise en \u0153uvre de ces technologies en milieu clinique, tout en participant \u00e0 la r\u00e9volution de l&rsquo;ARN en cours. <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">PROYTIC GmbH est une entreprise sp\u00e9cialis\u00e9e dans les bioanalyses et la pharmacocin\u00e9tique (PK) certifi\u00e9es BPL et conformes aux BPC, pour l&rsquo;analyse et la quantification de petites et grandes mol\u00e9cules, d&rsquo;enzymes et d&rsquo;oligonucl\u00e9otides. Pour en savoir plus sur <strong><a href=\"https:\/\/www.prolytic.de\/en\/services\/bioanalysis\/\" data-wpel-link=\"external\">les services de bioanalyse<\/a><\/strong> et les travaux avanc\u00e9s <strong><a href=\"https:\/\/www.prolytic.de\/en\/services\/rna-dna\/\" data-wpel-link=\"external\">sur l&rsquo;ADN\/ARN<\/a><\/strong> propos\u00e9s par PROYTIC, cliquez ici ou contactez-nous \u00e0 l&rsquo; <strong><a href=\"mailto:info@prolytic.de?subject=The%20revolution%20in%20COVID%20vaccine%20development\" data-wpel-link=\"internal\">adresse info@prolytic.de<\/a><\/strong> . <\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":6,"featured_media":27476,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[257],"tags":[],"class_list":["post-27474","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bioanalyse"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID | Groupe Kymos<\/title>\n<meta name=\"description\" content=\"Dr Meike Saul, TU Darmstadt\u00a0: La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID. Analyse des microARN avec Prolytic\/Kymos.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID | Groupe Kymos\" \/>\n<meta property=\"og:description\" content=\"Dr Meike Saul, TU Darmstadt\u00a0: La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID. Analyse des microARN avec Prolytic\/Kymos.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-01T11:23:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-03T18:00:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2021\/07\/RNA-Technology-Meike-Saul_srt-e1658232382872.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"554\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Joan Puig de Dou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joan Puig de Dou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/\"},\"author\":{\"name\":\"Joan Puig de Dou\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"headline\":\"La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID-19\",\"datePublished\":\"2021-02-01T11:23:35+00:00\",\"dateModified\":\"2025-12-03T18:00:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/\"},\"wordCount\":1323,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/07\\\/RNA-Technology-Meike-Saul_srt-e1658232382872.png\",\"articleSection\":[\"Bioanalyse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/\",\"name\":\"La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID | Groupe Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/07\\\/RNA-Technology-Meike-Saul_srt-e1658232382872.png\",\"datePublished\":\"2021-02-01T11:23:35+00:00\",\"dateModified\":\"2025-12-03T18:00:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"description\":\"Dr Meike Saul, TU Darmstadt\u00a0: La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID. Analyse des microARN avec Prolytic\\\/Kymos.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/07\\\/RNA-Technology-Meike-Saul_srt-e1658232382872.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/07\\\/RNA-Technology-Meike-Saul_srt-e1658232382872.png\",\"width\":1000,\"height\":554,\"caption\":\"RNA development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\",\"name\":\"Joan Puig de Dou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"caption\":\"Joan Puig de Dou\"},\"description\":\"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/author\\\/joan-puig-de-dou\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID | Groupe Kymos","description":"Dr Meike Saul, TU Darmstadt\u00a0: La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID. Analyse des microARN avec Prolytic\/Kymos.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/","og_locale":"fr_FR","og_type":"article","og_title":"La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID | Groupe Kymos","og_description":"Dr Meike Saul, TU Darmstadt\u00a0: La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID. Analyse des microARN avec Prolytic\/Kymos.","og_url":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/","og_site_name":"Kymos","article_published_time":"2021-02-01T11:23:35+00:00","article_modified_time":"2025-12-03T18:00:39+00:00","og_image":[{"width":1000,"height":554,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/07\/RNA-Technology-Meike-Saul_srt-e1658232382872.png","type":"image\/png"}],"author":"Joan Puig de Dou","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"\u00c9crit par":"Joan Puig de Dou","Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/"},"author":{"name":"Joan Puig de Dou","@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"headline":"La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID-19","datePublished":"2021-02-01T11:23:35+00:00","dateModified":"2025-12-03T18:00:39+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/"},"wordCount":1323,"image":{"@id":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/07\/RNA-Technology-Meike-Saul_srt-e1658232382872.png","articleSection":["Bioanalyse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/","url":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/","name":"La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID | Groupe Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/07\/RNA-Technology-Meike-Saul_srt-e1658232382872.png","datePublished":"2021-02-01T11:23:35+00:00","dateModified":"2025-12-03T18:00:39+00:00","author":{"@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"description":"Dr Meike Saul, TU Darmstadt\u00a0: La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID. Analyse des microARN avec Prolytic\/Kymos.","breadcrumb":{"@id":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/07\/RNA-Technology-Meike-Saul_srt-e1658232382872.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/07\/RNA-Technology-Meike-Saul_srt-e1658232382872.png","width":1000,"height":554,"caption":"RNA development"},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/fr\/news\/la-revolution-dans-le-developpement-des-vaccins-contre-la-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/fr\/"},{"@type":"ListItem","position":2,"name":"La r\u00e9volution dans le d\u00e9veloppement des vaccins contre la COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/fr\/#website","url":"https:\/\/kymos.com\/fr\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c","name":"Joan Puig de Dou","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","caption":"Joan Puig de Dou"},"description":"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.","url":"https:\/\/kymos.com\/fr\/news\/author\/joan-puig-de-dou\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/27474","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/comments?post=27474"}],"version-history":[{"count":0,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/27474\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/media\/27476"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/media?parent=27474"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/categories?post=27474"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/tags?post=27474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}